A Phase 3, Multicenter, Randomized Study to Evaluate the Substitution of MARQIBO (Vincristine Sulfate Liposomes Injection, VSLI) for Standard Vincristine Sulfate Injection (VSI) in the Induction, Intensification, and Maintenance Phases of Combination Chemotherapy in the Treatment of Subjects = > 60 Years Old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Description: 

In this study we wish to compare giving a combination of drugs which will include either Vincristine sulfate (VSI) or Marqibo to treat your ALL. There are two treatments to be tested in this study. Some patients will receive combination therapy containing vincristine sulfate (VSI). VSI will be dosed as an IV infusion (into a vein) over 10 minutes. Other patients will receive combination therapy containing Marqibo. Marqibo will be dosed as an IV infusion (into a vein) over 60 minutes. The total duration of treatment will be up to 24 months.

Study Number: 

PH 208211

Phase: 
III
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01439347

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.